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Abstract 
The purpose of this study was to investigate biocompatibility of the human mesenchymal stem cells (hMSCs) with bovine 
bone tissue at the cellular level in vitro. Phenotypic analysis of cells was made by flow cytometry. Cells were grown on 
the bone for 12 days. Metabolic activity of cells was assessed with the MTS assay. The growth data were used to calculate 
the population doubling times. The scanning electron microscopy was used to verify the attachment of cells on the bone 
surface. The results were analyzed by using ANOVA test. Immunophenotypic characteristics were positive for CD105, 
CD90, CD73, and negative for CD34, CD45. The growth curves of stem cells of the 1st and the 2nd passages for both 
media, with and without, bovine bone were constructed. The increase of approximately 60% of the doubling time for 
mesenchymal cells co-cultivated with bovine bone tissue was observed for both passages in comparison with the control. 
Our study confirmed that human mesenchymal stem cells are able to adhere to the bovine bone, even not being modified 
with bone-targeting elements. The proliferation rate and metabolic activity of cells co-cultivated with bone decrease in 
comparison with the control. Better survival was observed for cells of the 1st passage. 
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Introduction  
The tissue engineering as a rapidly growing research 
discipline evolved from the biomaterial development. 
This interdisciplinary field of research applies the 
principles of engineering to life sciences. The tissue 
engineering covers a broad range of therapeutic and 
diagnostic applications. The regeneration or reparation 
of damaged tissue is the main challenge in this field of 
investigation. Understanding the mechanisms of tissue 
regeneration is inevitable in healing (repairing) or 
replacement of tissue. In general, tissue engineering is 
the regeneration of biological tissue using cells and 
supporting structures and/or biomolecules [1]. The 
tissue engineering implies the use of convenient 
connection to scaffolds, cells, biologically active 
 
 molecules for the manufacture of a functional tissue. 
Another object of interest is to assemble a functional 
design that renews, maintains or improves the damaged 
tissue or the whole organ [2]. 
The successful tissue engineering relies on several 
specific criteria. One of them is the choice of cell type. 
The decision about the cell source plays a pivotal role in 
the design strategy of the tissue engineering for clinical 
applications. Key concern is to get the valid amount of 
the cells. The cells must be able to integrate into the 
matrix (e.g. bovine bone). Using growth factors, critical 
signaling molecules that instruct cells during 
development, cells will start to replicate and create new 
tissue. As a step toward engineering tissue by cell-based 
technologies is the use of native progenitor cells such as 
embryonic or adult stem cells. A specific subtype of 
multipotent stem cells, mesenchymal stem cells  
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(MSCs), belongs to the most promising and frequent 
research in the field of biomedical engineering and 
regenerative medicine. 
The permanent presence of stem cells in the tissues 
can help in regeneration of tissues in therapy. MSCs 
differentiate along a specific lineage pathway, thus 
replacing the damaged tissue, and/or induce tissue repair 
by endogenous cells through the paracrine release of 
trophic factors. In this way, MSCs offer the possibility 
of spontaneous reactions of the body and create 
conditions for a differentiation of cells of healthy tissue 
that replace damaged ones [3]. 
The bone marrow harbors the population of MSCs that 
possesses the potential to differentiate into bone, 
cartilage and fat [4]. When MSCs injected into cardiac 
muscle, they acquire the phenotype of cardiac myoblasts 
[5]. These characteristics indicate that MSCs can be 
used as powerful tools in reconstructive medicine [6]. 
MSCs transplanted into the bone and cartilage defects 
are able to differentiate into osteoblasts and cartilage 
and can repair damaged tissue by newly synthesized 
bone or hyaline cartilage, respectively [7–9]. To date, 
MSCs from various species have been studied. The 
bovine experimental model is being widely used in 
experiments in vivo and in vitro, but there is limited 
information about the regenerative effect of human 
mesenchymal stem cells on bovine bone tissue. 
The tissue engineering is also looking for suitable 
material for the bone transplants, which in combination 
with MSCs can rapidly repair the bone damage. There is 
a large number of candidates for a transplant on one side, 
but insufficient supply of tissues and organs from human 
donors on the other. Therefore, the aim of this study was 
the preliminary evaluation of survival of human 
mesenchymal stem cells on bovine bone tissue to 
understand the mechanisms of bone remodeling and 
repair. This study was performed on the basis of the 
hypotheses that bovine bone elicit differential stem cell 
response and may be osteoinductive, and that stem cells 
isolated from human bone marrow can adhere to bovine 
bone when seeded on this type of scaffold. This 
investigation is aimed at analyzing the potential of 
bovine bone to function as hMSCs carriers and to induce 
their osteogenic differentiation. 
Materials and methods  
Human mesenchymal stem cells were obtained from 
bone marrow. Bone marrow cells were isolated from the 
knee of patient during orthopedic surgery (Department 
of Trauma Surgery, Louis Pasteur University Hospital 
in Košice, Slovakia). The cells were donated by 68-year-
old man after informed consent. The written informed 
consent was obtained from the patient in accordance 
with the national ethical guidelines. Bone marrow was 
transported to the laboratory of Associated Tissue Bank 
of Louis Pasteur University Hospital in Košice on ice in 
a portable cooling container. Mononuclear cells were 
isolated by loading bone marrow sample into the lysing 
solution, which is important for lysis of erythrocytes. 
After centrifugation of lysate at 1500 RPM for 
20 minutes at room temperature, the hMSCs layer was 
removed from the interphase and washed twice with 
Phosphate Buffered Saline (PBS, Invitrogen, USA). 
Then they were seeded into uncoated T75 flask 
(Sarstedt, Germany) at a cell concentration of 
1×105 cells per square centimeter. Cells were cultured in 
basic growth medium (KKM) consisting of alpha-
minimum essential medium (α-MEM) (Lonza, Switzer-
land) with 100 U/ml penicillin, 0.1 mg/ml streptomycin 
(Lonza, Switzerland), 2 mmol/l L-glutamine (Lonza, 
Switzerland), 0.025 mg/ml amphotericin B (Lonza, 
Switzerland) with 15% (vol/vol) of pre-screened Fetal 
Bovine Serum. Cultures were maintained in a humidi-
fied atmosphere with 5% CO2 at 37°C. After incubation 
for 3 days, the medium was changed for the first time, 
later as needed. After reaching approximately from 60% 
to 80% confluence, the adherent cells were detached by 
treatment with 0.05% (vol/vol) trypsin/1 mmol/l EDTA 
solution (Gibco, USA). For our experiments, only cells 
from the first and the second passages (P1, P2) were 
used. 
Flow cytometry analysis 
For evaluation of surface markers expression, cell 
suspension was incubated for 30 minutes with 
phycoerythrin-conjugated antibodies against following 
human antigens, CD105 clone 43A3 (BioLegend, 
USA), CD90-PE clone 5E10 (BD Biosciences, USA), 
CD73-PE clone AD2 (Miltenyi Biotec, Germany), 
which had to be positive, and also to the specific 
hematopoietic cell surface antigens, fluorescein 
isothiocyanate-conjugated antibodies against human 
antigens CD34 clone AC136 (Miltenyi Biotec, 
Germany), CD45-FITC clone 5B1 (Miltenyi Biotec, 
Germany), which had to be negative. Samples were 
analyzed with a FACS Calibur (BD Biosciences, USA) 
and the CellQuest software (BD Biosciences, USA). 
Bovine bone tissue  
Bovine bone tissue was obtained from University of 
Veterinary Medicine and Pharmacy in Košice. Bovine 
bone tissue was processed according to the standard 
essential laboratory procedures of Associated Tissue 
Bank of Louis Pasteur University Hospital in Košice. At 
first, bone was stripped of soft tissues and cartilage. The 
preparing samples for experimental purposes consisted 
in cutting the bone into matrices of 5×5×5 mm size. 
Matrices were partially deproteinized by 0.07 mol/l 
sodium phosphate and subsequently treated with the 
same solution for 16 hours at room temperature. After 
intensive washing with distilled water, the samples were 
being demineralized in 0.5 mol/l HCl for 2 hours at room 
temperature. After demineralization, the samples were 
equilibrated with distilled water and sterilized using 
 61 
 
Lekar a technika – Clinician and Technology 2018, vol. 48(2), pp. 59–65 
ISSN 0301-5491 (Print), ISSN 2336-5552 (Online) 
ORIGINAL RESEARCH 
chemical sterilization solution of 0.36 mol/l peracetic 
acid, 4.40 mol/l ethanol and distilled water. Chemical 
sterilization lasted 24 hours under vacuum (0.5–0.6 bar) 
at room temperature. After sterilization, the samples 
were equilibrated with sterile distilled water and saline 
under aseptic conditions. 
Viable cell count and test 
Proliferations of hMSCs were measured using 
standard colorimetric test. Briefly, cell suspensions 
containing 15×103 viable cells were cultivated in 96-
well tissue culture plates (Sarstedt, Germany) in 
medium in a final volume of 200 μl in duplicates. The 
plate with bovine bone tissue was treated as the sample 
and the plate without bone tissue as the control. Bovine 
bone tissue with medium served as a negative control. 
The sample, the positive and the negative control were 
measured parallel. The first experiment was made 
approximately 24 hours after seeding. The optical 
density of each well was measured at 490 nm in a TriStar 
LB 941 device (Berthold Technologies, Germany). The 
obtained values were used to calculate a percentage of 
metabolic activity in comparison with controls 
considered to have 100% metabolic activity. Cells were 
stained with trypan blue (Sigma Aldrich, USA) with 
a 1:9 ratio of trypan blue to the cell suspension. Cells 
were counted in a Bürker counting chamber under light 
microscopy. Dark blue cells were evaluated as dead 
ones. The growth curves were constructed for both the 
sample and the control. Metabolic activity of the first 
passages (P1) as well as the second passages (P2) of  
 
hMSCs was evaluated. The whole experiment took 
12 days. Proliferation was observed on the first, on the 
fifth, on the ninth and on the twelfth day of the cell 
growth. 
Scanning electron microscopy  
Scanning electron microscope was used to examine 
adhesion and proliferation of human mesenchymal stem 
cells on bovine bone blocks. After 14 days of 
co-cultivation, samples were washed with PBS, fixed 
with 2.5% glutaraldehyde (Fluka-Biochemika, 
Switzerland) in 0.1 mol/l sodium cacodylate buffer 
(pH 7.2) (Merck-Darmstadt, Germany) at 4°C for 
24-hour periods and post fixed with 1% osmium 
tetraoxide (WC Heraeus GmbH, Germany) for 3 hours 
and washed with PBS. Then samples were immersed 
into isoamylacetate, dehydrated through an ethanol 
graded series and critical-point dried. Samples were 
attached to an aluminium stub and the sputter coated 
with gold prior to the observation. The surfaces of 
bovine bone tissue, with or without cells, were inspected 
by using the scanning electron microscope JSM 7000F 
(SEM Jeol, USA) at acceleration voltage of 20 kV. 
Statistical analysis 
The data are presented as the mean ± SEM (Standart 
Error of Mean). Significant differences between groups 
of means were analyzed by ANOVA. Statistical 
significance was assumed at the 95% confidence limit 
or greater (p<0.05). 
 
Fig. 1: Immunophenotypic bone marrow characteristics of hMSCs examined by flow cytometry: positive for CD105, 
CD90, CD73 and negative for CD34 and CD45. 
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Results  
To distinguish hMSCs from other cells in the bone 
marrow compartment, negative and positive hMSCs 
markers proposed by the International Society for Cell 
Therapy were used. Immunophenotyping of bone 
marrow hMSCs revealed that they were positive for 
several markers common to bone marrow hMSCs. The 
cell-surface markers analyzed using FACS 
(Fluorescence-Activated Cell Sorting) showed that the 
bone marrow hMSCs had a positive expression (≥95%) 
of CD105, CD90, CD73 and negative expression (≤2%) 
of hematopoietic surface markers CD34, CD45 (Fig. 1). 
The growth curves present activity of hMSCs for both 
cells of the first and the second passage in comparison 
with the control. The cell number for all samples 
increased up to the 12th day of cultivation with the 
typical sigmoid population dynamics for the control. 
The pattern of the adherent cells in the sample is slightly 
different; the curves did not reach the stabilization or 
equilibrium stage during the period of cultivation. There 
is also an obvious decreased number of attached cells of 
the sample observed in all days (except for the first day) 
in relation to the control. Compared to hMSCs seeded 
directly onto tissue culture plastic, the scaffold condition 
itself significantly reduces the growth of cells. 
The results of cell adhesion and proliferation of 
hMSCs are shown in Fig. 2. Five independent 
experiments were performed with the control (hMSCs) 
and the sample (hMSCs co-cultivated with bovine bone 
tissue). 
 
Fig. 2: Growth curves of hMSCs. The data represent the 
mean ± SEM of five independent experiments (respective 
SEM is less than the size of the symbol for each point). 
C – control (hMSCs without bovine bone tissue), P1 – 
the first passage of hMSCs, S – sample (hMSCs with 
bovine bone tissues), P2 – the second passage of hMSCs. 
The metabolic activity was measured and compared 
after seeding. Fig. 3 depicts metabolic activity of the cell 
population seeded on the bovine bone tissue of the first 
and the second passage in comparison with the control. 
Results show that the human mesenchymal cells have 
comparable metabolic activity through day 1 and 5 after 
seeding for both passages. Metabolic activity was 
decreasing up to the 12th day of cultivation. The 
statistically significant difference between groups of P1 
and P2 samples was assessed using ANOVA (*p<0.05). 
It can be seen from the graph that the cell growth on 
bovine bone tissue of the second passage cell population 
is significantly lower in comparison with the cell growth 
of the second passage on the 9th and on the 12th day of 
cultivation. 
Fig. 3: Metabolic activity of hMSCs co-cultivated with 
bovine bone tissue of the first and the second passage. 
Bars represent the mean ± SEM of five independent 
experiments. Statistical significance was assessed by 
using ANOVA (*p<0.05). 
To measure cell growth kinetics, two-fold increase 
(doubling) in the total number of cells at exponential 
phase of growth of cell cultures was calculated. 
Population doubling times of hMSCs directly correlates 
with replicative senescence, which is linked to loss of 
potency, as well as with genomic instability. Fig. 4 
illustrates population doubling times (PDTs) for hMSCs 
for both the first and the second passage of the control 
and the sample. PDTs show that cell cultures grow at 
different rates. A lower proliferation rate of sample in 
comparison with control was observed. An increase of 
approximately 60% of the doubling time for hMSCs 
co-cultivated with bovine bone tissue was observed for 
both passages. 
Fig. 4: Population doubling times (PDTs) of hMSCs for 
the first (P1) and the second passage (P2) for the control 
(C) and the sample (S). Values represent mean ± SEM 
for five experiments. 
According to the statistical analysis, the change in the 
growth rate of hMSCs co-cultivated with bovine bone 
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tissue between the first and second passage cell 
population (Tab. 1) was significant when p<0.005 and 
p<0.05. No significant difference was observed only 
between the cell cultures grow rates of the sample for 
both passages. 
Tab. 1: Statistical analysis of growth of hMSCs 
co-cultivated with bovine bone tissue after the first and 
the second passage. 
 C in P1 S in P1 C in P2 S in P2 
C in P1  p<0.005 p<0.005 p<0.005 
S in P1 p<0.005  p<0.005 p>0.05 
C in P2 p<0.005 p<0.005  p<0.005 
S in P2 p<0.005 p>0.05 p<0.005  
 
 
Fig. 5: The surfaces of bovine bone tissue without 
hMSCs. 
 
 
Fig. 6: The surfaces of bovine bone tissue with attached 
hMSCs. 
Finally, we evaluated the attachment of hMSCs to 
bovine bone tissue using scanning electron microscopy 
(Fig. 5, Fig. 6). SEM (Scanning Electron Microscope) 
micrograph shows the pore architecture of the bovine 
bone tissue without cells (Fig. 5) SEM micrograph 
bovine bone tissue with seeded cells demonstrates 
effective adhesion, spreading and intercellular contact of 
human mesenchymal stem cells within the pores bovine 
bone tissue during 14 days cultivation period (Fig. 6). 
Discussion  
Human MSCs have the potential of self-renewal and 
differentiation into multiple lineages including cartilage, 
adipose and bone tissue. Generally, MSCs are 
characterized by their ability to adhere under standard 
cell culture conditions, expressing CD44, CD73, CD90, 
CD105, but not CD45, CD34, and CD14 [10]. We used 
flow cytometry using a panel of monoclonal antibodies 
to verify the identity of MSCs extracted from human 
bone marrow. Immunophenotypic bone marrow 
characteristics of hMSCs examined by flow cytometry 
were positive, as expected, for CD105, CD90, and 
CD73, and negative for CD34 and CD45. 
Human mesenchymal stem cells have generated 
a great deal of interest because of their potential use in 
regenerative medicine and tissue engineering. 
Numerous preclinical and clinical studies have been 
performed to support the safety of using MSCs for cell-
based therapies. However, the ability of MSCs to 
produce intended result in vivo is still limited due to poor 
survival, retention, and engraftment of the cells. The 
treatment of musculoskeletal disorders has improved 
during the last 20 years due to the enormous progress in 
the understanding of basic biological and biomechanical 
principles. Based on this knowledge, new methods, 
modern rehabilitation programs and innovative 
approaches were developed and successfully applied for 
treatment [11]. Plenty of clinical and pre-clinical studies 
illustrate their therapeutic value in cell therapy [12], in 
dental medicine for rebuilding lost periodontal tissue 
[13] or in soft tissue-engineering [14] and bone tissue 
regeneration [15, 16], studying cell therapeutics for use 
in endotoxic shock, suggested that bone marrow-derived 
mesenchymal stromal cells may be more effective in 
shock therapy and adipose-derived stromal/stem cells 
may be positioned for continued exploration of 
immunomodulatory diseases. New generation of dermal 
equivalents for dermal tissue engineering was presented 
in the study of Schneider et al. [17]. They demonstrated 
the promotion of epithelial cell proliferation and 
extracellular matrix remodeling of collagen-embedded 
MSCs on the human fibroblast-derived dermal matrix. 
Bone tissue engineering is still a new research area. 
The subject of the study was to promote development of 
clinical applications to replace or restore the lost bone in 
case of orthopedic defects, stabilization of spinal 
segments, and restoration of bone defects in case of 
tumors and bone neoplasia and treatment of pseudo-
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arthrosis. Bone tissue engineering has already been used 
in craniofacial, maxillofacial, orthopedic reconstructive 
surgery, head surgery and trauma and neck surgery [18]. 
It may provide solutions for generating a new bone 
tissue with good mechanical and functional qualities. 
Reduction of the risks and expenses is possible by using 
allografts, autografts, metals and ceramics, and so on. 
According to the study of Rodrigues et al. [19], 
utilization of allografts in bone tissue engineering has 
several disadvantages consisting in potential immune 
response, transmission of diseases and induction of the 
loss of osteogenesis. Autografts have limitations due to 
the necessity of an additional surgery, anatomical and 
structural problems, limited donor bone supply and 
inadequate resorption rate during healing. Different 
biomaterials have been used as for example scaffolds or 
implants for bone tissue engineering [20–23] or artificial 
intervertebral discs [24] or part of endoprothesis [25]. 
Metals, alone or coated with bioactive and bioinert 
ceramics, have been used for load-bearing orthopedic 
applications, but problems due to metals corrosion, 
dense fibrous tissue formation on the bone-implant or 
ceramics-metal interface may occur [19]. For improving 
osteoinduction and osteoconduction, association of 
extracellular matrix scaffolds with osteogenic cells and 
differentiation and growth factors may be required [26]. 
The large number of candidates for a transplant on the 
one side and the insufficient supply of donated organs 
from human donors on the other, necessitate in 
alternative options. Such an alternative could also be the 
mechanisms of bone remodeling and repair with the aid 
of combinatorial approach including human 
mesenchymal stem cells and bovine bone tissue. Lately, 
a novel option for the delivery of human mesenchymal 
cells appeared there that employs bovine bone matrix as 
a scaffold [27]. Although MSCs differentiate into 
osteoblasts, naturally they do not migrate to bone. 
According to the studies examining the tropisms of 
MSCs to bone, MSCs can only be targeted to bone for 
bone regeneration by enhancing the transmigration of 
MSCs to the bone via the selectin-mediated cell 
adhesion pathway [28, 29]. Also, MSCs modified with 
bone-targeting polymer can be used to augment 
osteogenesis [30–32]. 
In our study, we tried to evaluate the survival of 
human mesenchymal stem cells delivered on bovine 
bone matrix as a scaffold. We examined the tropism of 
hMSC to bovine bone patches of unmodified hMSCs. 
The results show that bovine bone scaffolds can be used 
to harbour hMSCs and that bone can modulate human 
stem cell behaviour. hMSCs are able to adhere to the 
bovine bone even not being modified with bone-
targeting elements. However, it must be said, that the 
proliferation rate and metabolic activity for hMSCs 
co-cultivated with bovine bone decrease in comparison 
with the control. There are also observable differences 
in the behaviour of the first and the second passages of 
the cells, proliferation of the second passage is not as 
rapid as the proliferation of the first one. 
Conclusion  
This preliminary study is only the first step on the long 
way of examination of compatibility and validation of 
combinatorial approach using bones from other species 
and human MSCs for tissue engineering for 
transplantation. Therefore, future experimental studies 
need to focus on inducing multitudes of biochemical and 
physical cues to affect the microenvironment of the 
MSCs, which may enhance the desired efficacy. 
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